Evidence map›Paper›PMID 26266019›Full record

ArticleRare tumors2015

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.

Steven Attia, Scott H Okuno, Steven I Robinson, Nicholas P Webber, Daniel J Indelicato, Robin L Jones, Sanjay P Bagaria, Robin L Jones, Courtney Sherman, Kevin R Kozak and 4 more

Registry-linked trialOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Rare tumors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02048371 (SARC024), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02048371 phase2completednot on this map

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

TypeinterventionalSponsorSarcoma Alliance for Research through CollaborationRan2014 to 2022Enrolled131ConditionsLiposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, RhabdomyosarcomaArmsRegorafenib, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Activity of pazopanib inOncoscience · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Establishment of a novel patient-derived Ewing's sarcoma cell line, NCC-ES1-C1.In vitro cellular & developmental biology. Animal · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Steven AttiaMayo Clinic , Jacksonville, FL, USA.
Scott H OkunoMayo Clinic , Rochester, MN, USA.
Steven I RobinsonMayo Clinic , Rochester, MN, USA.
Nicholas P Webber3Aurora Healthcare , Milwaukee, WI, USA.
Daniel J Indelicato4University of Florida , Jacksonville, FL, USA.
Robin L JonesRoyal Marsden Hospital , London, UK.
Sanjay P BagariaRoyal Marsden Hospital , London, UK.
Robin L JonesMayo Clinic , Jacksonville, FL, USA.
Courtney ShermanMayo Clinic , Jacksonville, FL, USA.
Kevin R KozakMercy Medical Center , Janesville, WI, USA.
Cherise M CorteseMayo Clinic , Jacksonville, FL, USA.
Thomas McFarlandUniversity of Wisconsin , Madison, WI, USA.
Jonathan C TrentUniversity of Miami , FL, USA.
Robert G MakiMount Sinai Medical Center , New York, NY, USA.
WinnMed · USMayo Clinic in Arizona · USMayo Clinic in Florida · USMercy Medical Center · USMount Sinai Medical Center · USRoyal Marsden Hospital · GBUniversity of Miami · USUniversity of North Florida · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

Indexed as

Ewingpazopanibsarcoma

Identifiers

PMID26266019
PMCPMC4508650
OpenAlexW1879554030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.